-
Risks and Benefits of an Extended 10-year Tamoxifen Regimen for Breast Cancer; Is There More Pro than Con in Probiotics in Critically Ill Adults?; The ASH Position Paper on Orthostatic Hypotension
-
Chelation therapy for cardiovascular disease; statins and kidney injuries; chlorthalidone for hypertension; and FDA actions.
-
The FDA has approved a fixed combination of doxylamine succinate and pyridoxine for the treatment of nausea and vomiting due to pregnancy. This is a reintroduction of a product widely used between 1956 and 1983.
-
Use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes in stable patients with a history of myocardial infarction (MI). These results do not support the routine use of chelation therapy for treatment of patients who have had a prior MI.
-
This meta-analysis did not convincingly demonstrate a positive effect of gastric acid-suppressing treatment in patients with chronic cough.
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
-
-
Five days of steroid treatment was as effective as 14 days of treatment in preventing repeat exacerbations of COPD in patients presenting to the emergency department with COPD exacerbations.
